Intravascular NK-cell lymphoma: a case report and review of the literature

Yalan Bi1*, Zhen Huo1, Zhiyong liang1, Yunxiao Meng1, Congwei Jia1, Xiaohua Shi1, Lan Song2, Yufeng Luo1, Qing Ling1 and Tonghua Liu1

Abstract

Background: Intravascular NK-cell lymphoma (IVNKL) is an extremely rare variant of non-Hodgkin lymphoma. To our knowledge, there are only a few cases reported in the English literature. Here, a case of a 29-year-old male with IVNKL involving the skin of the trunk and 4 extremities and liver is presented. A comprehensive literature review is undertaken to summarize the clinical and pathological features of this disorder.

Findings: In our case, large neoplastic lymphoid cells are restricted to the lumen of small vessels and exhibit the phenotype of a true NK cell. The morphology and immunophenotype, positivity of EBER and NK-cell origin are similar to other IVNKL cases. In addition, some cases including ours carry a poor prognosis as multiple systems or vital organs are involved.

Conclusion: In summary, we report a case of an unusual intravascular lymphoma of NK-cell lineage that displays both clinical and pathological features and compare it with other differential diagnoses. It is important to recognize this rare entity to make an appropriate diagnosis and achieve a better understanding regarding the treatment and prognosis.

Keywords: Intravascular lymphoma, NK-cell lymphoma, Epstein-Barr virus

Background

Intravascular NK-cell lymphoma (IVNKL) was first reported by Santucci et al. in 2003 [1] and is revealed as an infiltration of large cells with an NK/T-cell phenotype (CD3ε+, CD56+, and markers for cytotoxicity +) that is localized strictly intravascularly. Most of these cases are Epstein-Barr virus nucleic acid EBER (Epstein-Barr virus-encoded small RNA) positive and T-cell receptor (TCR) gene rearrangement negative. Multiple organs may be involved, resulting in a variety of clinical presentations; however, the most common locations that are involved are the skin and the central nervous system (CNS). IVNKL is an aggressive lymphoma with a variable but mostly limited response to chemotherapy and an overall poor prognosis, especially for those patients with multi-system involvement.

Intravascular lymphoma (IVL) is a rare entity. This disorder was first described as angioendotheliomatosis proliferans systemisata by Pfleger and Tappeiner [2] in 1959. The neoplastic cells were initially believed to be of endothelial origin; however, subsequent immunohistochemical and molecular studies demonstrated the lymphoid nature of the neoplastic cells [3]. Most cases constitute a variant of an extranodal diffuse large B-cell lymphoma, and only approximately 10 % of the published cases are of T-cell or histiocytic origin [4]. To date, relatively few cases with an NK-cell lineage have been reported in the English literature (Table 1) [1, 5–12].

Here, we report on a 29-year-old male patient with IVNKL of the skin with secondary involvement of the liver and provide a brief literature review, aiming to (i) emphasize the diagnostic histopathologic features of this disease, (ii) avoid the trap of misdiagnosis of malignant or benign diseases, and (iii) achieve a better understanding of the character and treatment of this disease.
Findings

A 29-year-old man presented with erythematous plaques on the thighs and trunk, low fever, intermittent headaches, weight loss and leukopenia. His family history was significant, as his only sister had acute myeloid leukemia (M3) several years previously and was cured by chemotherapy. Physical examination revealed painful, subtle, ill-defined, irregular, blanching erythematous patches on the lower and upper extremities and trunk (Fig. 1a and b) and slight hepatosplenomegaly.

Table 1 Characters of reported cases of IVNKL

| Case number/case | Age/gender | Involved organ(s) | Treatment and follow up |
|------------------|------------|-------------------|------------------------|
| 1. Santucci et al. [1] | 54/M | Skin, CNS | Chemotherapy, died 17 months after diagnosis |
| 2. Wu et al. [5] | 41/M | Skin | Chemotherapy, alive and event free at 12 months |
| 3. Wu et al. [5] | 47/F | CNS, bone marrow, kidneys, ovaries, cervix | Treatment unclear, died half a month after diagnosis |
| 4. Kuo et al. [6] | 71/F | Skin | Alive 5 months after diagnosis without treatment |
| 5. Song et al. [7] | 40/F | Skin | Chemotherapy, alive and event free at 7 months |
| 6. Nakamichi et al. [8] | 23/F | Skin | Chemotherapy and stem cell transplantation, died of acute GVHD 9 months after diagnosis |
| 7. Cerroni et al. [9] | 63/M | Skin | Chemotherapy, died 6 months after diagnosis |
| 8. Liao et al. [10] | 42/F | Skin | Chemotherapy and radiotherapy, alive with disease 14 months after diagnosis |
| 9. Gebauer et al. [11] | 72/M | Skin, bone marrow, CNS | Chemotherapy, died 7 months after diagnosis |
| 10. Liu et al. [12] | 37/F | Skin, CNS | Chemotherapy, died 13 months after diagnosis |
| 11. Our case | 29/M | Skin, liver | Chemotherapy, died 3 months after diagnosis |

| Case number/case | Immunophenotypes | PCR-TCR |
|------------------|------------------|---------|
|                  | CD3  | CD4  | CD5 | CD8 | CD20 | CD30 | CD56 | Cytotoxic markers | EBER |
| 1. Santucci et al. [1] | +   | -    | NA | -   | -   | +    | +    | +               | ND   |
| 2. Wu et al. [5] | +   | -    | -   | -   | -   | +    | +    | +               | P    |
| 3. Wu et al. [5] | +   | -    | -   | -   | NA  | +    | +    | -               | P    |
| 4. Kuo et al. [6] | +   | -    | -   | -   | -   | +    | +    | +               | P    |
| 5. Song et al. [7] | +   | -    | NA  | -   | NA  | +    | +    | +               | P    |
| 6. Nakamichi et al. [8] | +   | NA  | NA  | NA  | +    | +    | +    | +               | ND   |
| 7. Cerroni et al. [9] | +   | -    | NA  | -   | NA  | +    | +    | +               | P    |
| 8. Liao et al. [10] | +   | -    | -   | -   | -   | +    | +    | +               | ND   |
| 9. Gebauer et al. [11] | +   | -    | NA  | -   | -   | +    | +    | +               | P    |
| 10. Liu et al. [12] | +   | -    | -   | -   | -   | +    | +    | +               | ND   |
| 11. Our case | +   | -    | -   | -   | +   | +    | +    | +               | P    |

M, male; F, female
GVHD, graft-versus-host disease
NA, not available
cytotoxic markers, TIA-1 and/or granzyme B and/or perforin
PCR-TCR, polymerase chain reaction analysis of the T-cell receptor g gene
P, polyclonal smear

Fig. 1 a and b Red-violaceous ill-defined and irregular plaques on the lower extremities and trunk
A biopsy of the erythematous plaques on the right thigh was performed. The specimen consisted of skin and subcutaneous tissue and measured 1.2 × 0.9 × 0.5 cm. The sample was fixed in 10 % buffered formalin and embedded in paraffin. Four-micron sections were cut and stained with hematoxylin and eosin. The cutaneous lesions contained clusters of atypical lymphoid intravascular cells that were occluding and expanding the lumina of the dilated vessels throughout the subcutaneous tissue (Fig. 2a and b). Reactive lymphocytes were observed and were aggregated around the vessels. The tumor cells were discohesive, large, and pleomorphic and had irregular enlarged nuclei with scanty cytoplasms. Mitotic figures and tumor cell necrosis were obvious.

Based on immunohistochemical staining, the phenotype of the tumor cells was CD3+, CD43+, CD56+, TIA-1+, CD30+, CD4-, CD5-, CD7-, CD8-, CD20- and CD79a-. Approximately 90 % of the tumor cell nuclei were Ki-67 positive. The vascular endothelial cells were positive for CD31 and CD34, which demonstrated the intravascular nature of the neoplastic cells (Fig. 3a, b, c and d). In situ hybridization for EBER revealed positive signals in virtually all tumor cell nuclei (Fig. 4). DNA extracted from formalin-fixed paraffin-embedded samples was analyzed by polymerase chain reaction (PCR). The molecular study demonstrated a germline configuration of TCR genes without rearrangements (Fig. 5).

Further hematologic analysis demonstrated a normal peripheral blood count (White blood cell count, 5.66×10^9/L, Red blood cell count, 4.20×10^12/L, Platelet count, 205×10^9/L) and a deterioration of liver function. A bone marrow biopsy and cytological examination of
cerebrospinal fluid revealed no evidence of tumor involvement.

A diagnosis of IVL of the natural killer cell type was established 6 months after the appearance of initial skin lesions. The patient received 2 cycles of combination chemotherapy (cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone; Hyper CVAD). However, clinical and computed tomography scans revealed multiple low-density hepatic masses, indicating liver involvement (Fig. 6a and b). The status of the patient deteriorated rapidly and he had a fever of 38.5°-39 °C. He died of multi-organ failure 3 months after diagnosis.

Discussion

Among the 11 reported cases of IVNKL, including the cases originally published in English and ours, six (54.5 %) were reported from Asia (2 from China, 2 from Taiwan, 1 from Japan and 1 from Korea), which is consistent with the distribution characteristics of extranodal NK/T-cell lymphoma, nasal type, which has a higher incidence in East Asia and Latin America, with EBV infection occurring in some cases [13]. Of the 11 patients, six were female and five were male. The ages ranged from 23 to 72 years (median, 47 years). Dermatological manifestations were observed in 10 (91 %) cases. Multisystem involvement occurred in 5 patients, and 4 of 5 were CNS involvement. After a follow-up that ranged from half a month to 17 months, 7 of 11 patients died, and only 4 of 11 experienced temporary remission.

In the 11 cases in which the morphology of the IVNKL was described, the tumor cells were all confined within the vessels and had large cell sizes with pale or eosinophilic cytoplasms and irregular hyperchromatic nuclei. Mitotic figures and necrosis were routinely observed. In all 11 cases, typical NK cell immunophenotypes were observed: CD3+; CD56+; TIA-1+; granzyme
B+; perforin+; CD4-; CD5-; CD8- and CD20-. EBER detection was performed in 11 cases and was positive in 10 of the 11 cases, indicating Epstein-Barr virus (EBV) infection. T-cell gene rearrangement analysis was performed in 7 of the 11 cases and was negative, confirming an NK-cell origin.

For diagnosis, large neoplastic lymphoid cells of IVNKL are restricted to the lumen of small vessels and exhibit the phenotype of a true NK cell, characterized by tumor cells with a CD2+, cytoplasmic CD3ε+ and CD56+ immunophenotype and germline configuration of the TCR gene [14]. Tumor cells also expressed cytotoxic granules, including TIA-1, granzyme B and perforin, and were often EBV positive. Thus, the similar morphology and immunophenotype of other cases, positivity of EBER and NK-cell origin help to confirm the diagnosis of our case as IVNKL.

As so far, IVNKL is not classified within the World Health Organization classification subtypes [15]. However, in view of the unique characteristics of this disease, the diagnosis should be independent to collect more data to help with further study of this disease. Because of the similar morphology and immunophenotypes, TCR rearrangement results, and EBV infection status of intravascular NK-cell lymphoma, extranodal NK/T-cell lymphoma, nasal type (ENKTCL) and aggressive NK-cell leukemia [16, 17], we suggest that IVNKL should be distinguished from the other two subtypes. Patients with IVNKL had no nasal symptoms and obvious abnormalities in the peripheral blood but had the hallmark of intravascular dissemination of tumor cells. In ENKTCL and aggressive NK-cell leukemia, tumor cells were distributed in tissues rather than deposited in blood vessels. The other differential diagnoses of IVNKL include IVL of other lineages (in which the tumor cells have typical immunophenotypes, such as being positive for B or T-cell markers), metastatic neoplasms (for example melanoma or breast cancer, which are validated by medical history and immunochemical staining), and numerous inflammatory processes, including drug reactions and insect bites, showing atypical intravascular CD30+ T-cell proliferation mimicking intravascular lymphoma (which includes variable numbers of intravascular CD30-positive cells, but the extent of the intravascular proliferation is much less florid, and the cells show a mixture of CD4 and CD8 positivity without a monoclonal T-cell population by molecular testing) [18].

Regarding etiological hypotheses, we believe that not only EBV infection but also genetic inheritance is somehow involved in the pathogenesis of this rare lymphoma because of this patient’s remarkable family history. IVNKL treatments are ineffective and include chemotherapy, radiotherapy, and even stem cell transplantation, which cannot change the poor prognosis. Because patients with clinical presentation confined to skin have a better prognosis, the poor outcome may be due to multisystem or vital organ involvement.

Consent
Written informed consent was obtained from the patient’s parents prior to publication of this case report.

Fig. 5 Molecular studies revealed a germline configuration for the T-cell receptor that is consistent with the possibility of an NK-cell origin. (L = Control Size Ladder for samples of unknown quantity and quality, M = DNA ladder marker, TB (A,B,C), TD and TG (A,B) represent 6 tubes of master mixes for targeting different regions of TCR genes)
and the accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations
INKL: Intravascular NK-cell lymphoma; EBER: Epstein-Barr virus-encoded small RNA; TCR: T-cell receptor; CNS: Central nervous system; IVL: Intravascular lymphoma; DNA: Deoxyribonucleic acid; PCR: Polymerase chain reaction; EBV: Epstein-Barr virus.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
YLB and ZH were the main authors of the paper, and they equally worked the case and drafted the manuscript. ZYL and YXM participated in the design of the study. CWJ and XHS were responsible for the clinical data. LS participated in the radiological analysis. YFL conducted the immunohistochemical study. QL conducted the molecular study. THL was the primary pathologist involved in the case, made the final diagnosis, and was the main editor of the body of the text. All of the authors read and approved the final manuscript.

Acknowledgements
We thank James B. who provided medical writing services on behalf of American Journal Experts, LLC.
Author details
1Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, DongCheng District, Beijing 100730, China.
2Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Received: 9 January 2015 Accepted: 26 June 2015
Published online: 01 July 2015

References
1. Santucci M, Pimpinelli N, Massi D, Kadin ME, Meijer CJ, Müller-Hermelink HK, et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer. 2003;97:610–27.
2. Pfleger L, Tappeiner J. Zur kenntnis der systemisierten endotheliomatose der cutanen blutgefaesse. Hautartz. 1959;10:359–63.
3. Sheibani K, Battifora H, Winberg CD, Burke JS, Ben-Era J, Ellinger GM, et al. Further evidence that “malignant angioendotheliomatosis” is an angiotropic large-cell lymphoma. N Engl J Med. 1986;314:493–8.
4. Gleason BC, Brinster NK, Granter SR, Pinkus GS, Lindenman N, Miller DM. Intravascular cytotoxic T-cell lymphoma: a case report and review of the literature. J Am Acad Dermatol. 2008;58:290–4.
5. Wu H, Said JW, Ames ED, Chen C, McWhorter V, Chen P, et al. First reported cases of intravascular large cell lymphoma of the NK cell type: clinical, histologic, immunophenotypic, and molecular features. Am J Clin Pathol. 2005;123:603–11.
6. Kuo TT, Chen MJ, Kuo MC. Cutaneous intravascular NK-cell lymphoma: report of a rare variant associated with Epstein-Barr virus. Am J Surg Pathol. 2006;30:1197–201.
7. Song DE, Lee MW, Ryu MH, Kang DW, Kim SJ, Huh J. Intravascular large cell lymphoma of the natural killer cell type. J Clin Oncol. 2007;25:1279–82.
8. Nakamichi N, Fukuhara S, Aoaza K, Morii E. NK-cell intravascular lymphomatosis—a mini-review. Eur J Haematol. 2008;81:1–7.
9. Cerroni L, Massone C, Kutzner H, Mentzel T, Umbert P, Kerl H. Intravascular large T-cell or NK-cell lymphoma: a rare variant of intravascular large cell lymphoma with frequent cytotoxic phenotype and association with Epstein-Barr virus infection. Am J Surg Pathol. 2008;32:891–8.
10. Liao JB, Hsieh PP, Hwang YC, Lin SL, Wu CS. Cutaneous intravascular natural killer-cell lymphoma: a rare case and review of the literature. Acta Derm Venereol. 2011;91:472–3.
11. Gebauer N, Nissen EJ, Driesch P, Feller AC, Merz H. Intravascular natural killer cell lymphoma mimicking mycosis fungoides: a case report and review of the literature. Am J Dermatopathol. 2014;36:e100–4.
12. Liu Y, Zhang W, An J, Li H, Liu S. Cutaneous intravascular natural killer-cell lymphoma: a case report and review of the literature. Am J Clin Pathol. 2014;142:243–7.
13. Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007;139:532–44.
14. Siu LL, Chan JK, Kwong YL. Natural killer cell malignancies: clinicopathologic and molecular features. Histol Histopathol. 2002;17:539–54.
15. Swerdlow SH. WHO classification of tumors of haematopoetic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008.
16. Li S, Feng X, Li T, Zhang S, Zuo Z, Lin P, et al. Extranodal NK/T-cell lymphoma, nasal type: a report of 73 cases at MD Anderson Cancer Center. Am J Surg Pathol. 2013;37:14–23.
17. Kwong YL. The diagnosis and management of extranodal NK/T-cell lymphoma, nasal-type and aggressive NK-cell leukemia. J Clin Exp Hematol. 2011;51:21–8.
18. Riveiro-Falkenbach E, Fernández-Figueras MT, Rodríguez-Penalt L. Benign atypical intravascular CD30(+)-T-cell proliferation: a reactive condition mimicking intravascular lymphoma. Am J Dermatopathol. 2013;35:143–50.